Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JNJ 55308942

Next Previous
X
Search
Drug Profile

JNJ 55308942

Alternative Names: JNJ-55308942

Latest Information Update: 02 Aug 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janssen-Cilag
  • Class Anti-inflammatories; Antidepressants; Antiepileptic drugs; Behavioural disorder therapies; Neuropsychotherapeutics
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Bipolar depression
  • No development reported Epilepsy; Inflammation; Inflammatory bowel diseases; Mood disorders

Most Recent Events

  • 17 May 2024 anssen Pharmaceutica completes a phase II trial in Bipolar depression in Canada (PO) (NCT05328297) (EUCT2021-004790-3)
  • 03 Jun 2022 Phase-II clinical trials in Bipolar depression in Spain, Poland, USA (PO) (NCT05328297)
  • 14 Apr 2022 Janssen Pharmaceutica plans a phase II trial in Bipolar disorder in US, Poland, Spain (Oral, Capsules) (NCT05328297)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top